Neurocrine Biosciences NBIX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $197.9M+2,405% | $153.7M+49.1% | $209.5M+61.4% | $107.5M+65.4% | $7.9M-81.8% | ||
| $7.2M+9.1% | $6.4M+3.2% | $6.7M+19.6% | $6.3M-1.6% | $6.6M+24.5% | ||
| $57.2M+8.3% | $58.6M-11.7% | $53.7M+29.4% | $52.8M+22.5% | $52.8M+18.7% | ||
| -$61.1M-346% | $48.2M+254% | $168.3M+582% | -$37.4M+9.4% | -$13.7M+12.2% | ||
| $28.6M— | —— | —— | —— | $0— | ||
| $81.4M+121% | —— | $132.3M+926% | $79.7M+353% | $36.9M+227% | ||
| -$14.3M-377% | $76.5M-1.0% | $55.8M+26.2% | $30.9M+152% | -$3M+83.9% | ||
| $0-100% | —— | $200K— | —— | $700K-79.4% | ||
| $119.8M+678% | —— | —— | —— | $15.4M— | ||
| $100K-90.0% | $1.1M+22.2% | $1M+11.1% | $1M+11.1% | $1M+11.1% | ||
| $25.3M+183% | —— | $30.6M+281% | -$6.7M+66.3% | -$30.6M-2,013% | ||
| $2.7M-62.5% | —— | $6.6M+2,100% | $7.1M— | $7.2M— | ||
| $145.8M+125% | $388.4M+60.2% | $227.5M+44.0% | $102M+57.9% | $64.8M-50.3% | ||
| $9.1M-15.0% | $0-100% | $13.2M+63.0% | $12.5M+7.8% | $10.7M-4.5% | ||
| $819.5M+200% | $323M+3.6% | $408.5M+75.7% | $315.1M+64.4% | $273.2M-14.7% | ||
| $63.2M— | —— | —— | —— | $0— | ||
| -$506.2M-3,665% | -$52.9M+22.5% | -$196.7M— | -$29M-2.8% | $14.2M+126% | ||
| $54M-64.0% | —— | —— | $17.7M— | $150M— | ||
| $23.6M-26.5% | $37.3M+273% | $45.6M+72.7% | $14.4M-8.9% | $32.1M-54.1% | ||
| $55.7M— | —— | —— | —— | $0— | ||
| -$86.1M+27.0% | —— | —— | -$3.3M+98.9% | -$117.9M-269% | ||
| -$446.5M-1,048% | $372.8M+421% | $76.2M-63.6% | $69.9M+127% | -$38.9M-127% | ||
| $300K-50.0% | $7.8M-89.3% | $1.1M-97.9% | $71.9M-22.4% | $600K+200% | ||
| $1.3M-71.7% | $2M-64.3% | $2.7M-58.5% | $3.4M-51.4% | $4.6M-35.2% | ||
| $100K-90.0% | $1.1M+22.2% | $1M+11.1% | $1M+11.1% | $1M+11.1% | ||
| $2.7M-62.5% | —— | $6.6M+2,100% | $7.1M— | $7.2M— | ||
| —— | $6.7M+158% | $6.7M+158% | $6.7M+158% | $6.7M+158% | ||
| $259.2M-13.0% | $267.7M+6.7% | $225M-15.2% | $298.6M+70.5% | $298.1M+7.9% | ||
| $1.4M-48.1% | $1.6M+14.3% | —— | —— | $2.7M+145% | ||
| $136.7M+153% | $390.8M+66.2% | $214.3M+43.0% | $89.5M+68.9% | $54.1M-54.6% | ||
| $136.7M+153% | $390.8M+66.2% | $214.3M+43.0% | $89.5M+68.9% | $54.1M-54.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Neurocrine Biosciences generate?
- Neurocrine Biosciences (NBIX) generated $863.7M in operating cash flow over the trailing twelve months.
- What is Neurocrine Biosciences's free cash flow?
- After $34.8M of capital expenditures, Neurocrine Biosciences's free cash flow was $831.3M over the trailing twelve months, up 68.9% year over year.
- Where does Neurocrine Biosciences's cash flow data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
